Literature DB >> 3461870

HTLV-III infection in Canada in 1985.

P W Neumann, B J Benning, D G Robinson, N Gilmore, M V O'Shaughnessy.   

Abstract

More than 25 000 serum specimens have been tested for antibody to human T-lymphotropic virus type III (HTLV-III) at the Laboratory Centre for Disease Control, Ottawa, since August 1984. In 1985 the prevalence rates of antibody positivity among selected risk groups were as follows: patients with Kaposi's sarcoma, 77%; patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC), 66%; patients with hemophilia, 65%; symptomatic homosexual men, 48%; cohabitants of patients with AIDS, ARC or antibody to HTLV-III, 24%; and intravenous drug abusers, 13%. No case of accidental parenteral exposure has resulted in seroconversion. Eight cases of AIDS, all in antibody-positive patients, have been associated with blood transfusions. A testing protocol based on risk-group information is proposed for diagnostic laboratories.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3461870      PMCID: PMC1491537     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  3 in total

1.  Risk factors in pediatric AIDS.

Authors:  J H Joncas; N Lapointe; M V O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-03-15       Impact factor: 8.262

2.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

3.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

  3 in total
  5 in total

1.  Laboratory evidence of human immunodeficiency virus infection in Canada in 1986.

Authors:  P W Neumann; M V O'Shaughnessy; M J Garnett
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

2.  Laboratory evidence of human viral and selected nonviral infections in Canada in 1985.

Authors: 
Journal:  CMAJ       Date:  1986-11-15       Impact factor: 8.262

3.  Transmission of human immunodeficiency virus: ethical considerations and practical recommendations.

Authors:  I Kleinman
Journal:  CMAJ       Date:  1987-10-01       Impact factor: 8.262

4.  Laboratory diagnosis of the first cases of HIV-2 infection in Canada.

Authors:  P W Neumann; M V O'Shaughnessy; D Lepine; I D'Souza; C Major; B McLaughlin
Journal:  CMAJ       Date:  1989-01-15       Impact factor: 8.262

5.  Performance characteristics of recombinant enzyme immunoassay to detect antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2 and to measure early antibody responses in seroconverting patients.

Authors:  R A Galli; S Castriciano; M Fearon; C Major; K W Choi; J Mahony; M Chernesky
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.